Literature DB >> 21977103

Lamotrigine-induced SIADH in a child with central diabetes insipidus.

Huseyin Kılıç1, Barış Ekici, Yakup Ergul, Sabiha Keskin, Serap Uysal.   

Abstract

Entities:  

Year:  2011        PMID: 21977103      PMCID: PMC3173930          DOI: 10.4103/1817-1745.84422

Source DB:  PubMed          Journal:  J Pediatr Neurosci        ISSN: 1817-1745


× No keyword cloud information.
Dear sir, Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is caused by the elevated level of vasopressin resulting in excessive free water reabsorbtion and hyponatremia.[1] Drugs can induce SIADH by stimulating the release of antidiuretic hormone secretion (ADH) from the posterior pituitary gland or potentiating the renal action of ADH.[2] Among the antiepileptics, carbamazepine (CBZ) and oxcarbamazepine are the drugs that are most frequently accused of hyponatremia.[34] Seven and a half year-old-girl, an operated case of craniopharyngioma, 2 years back was on hormone replacement therapy because of panhypopituitarism, was admitted with vomiting and four generalized tonic-clonic seizures since a day. She had been receiving carbamazepine (20 mg/kg) and valproate (40 mg/kg) since last year. On admission, physical examination was normal except for weak right pupillary reflex and extensor plantar on the left side. Complete blood count (Hct: 32%), blood electrolytes, and d-dimer were all normal. Urinalysis was 2(+) for acetone, thought to be due to vomiting. CT scan head was normal. MRI scan brain revealed stable postoperative changes. EEG revealed spikes and slow waves at the right parietooccipital area. Serum levels of valproate was 88 μg/mL and carbamazepine was 6.5 μg/mL. Lamotrigine (LTG) from 0.25 mg/kg was added for refractory seizures and the patient became seizure free after 3 days. On the fifth day of LTG treatment, her urine output decreased to 320 cc/24 h, frequency of convulsions increased up to 3/h and decline in the level of consciousness was noticed, the Glascow Coma Score was 9. Repeated blood chemistry revealed as Na: 114 and 103 meq/L after 6 h, urea: 14 mg/dL,creatinine: 0.25 mg/dl, and uric acid: 1.2 mg/dl. Hematocrit was 30%. Blood and urine osmolality were 275 and 560 mosm/L, respectively. Urine-specific gravity was 1027, and urine Na was 230 mmol/L. Since she had no eyelid or tibial edema, blood tension of 105/65 mmHg, volume overload or dehydration with the preceding findings, SIADH was the diagnosis. At first, the desmopressin dose was decreased from 0.1 to 0.025 mg, and fluid uptake was restricted to 750 mL/day; but hyponatremia persisted below 125 meg/L. LTG was discontinued completely with presumption of drug-induced SIADH. On the third day of withdrawal, serum sodium was 128 meq/L and on the seventh day it raised to 159 meq/L, therefore desmopressin dose was increased again to 0.05 mg. In the third week of follow-up, all the biochemical parameters were normal and seizures subsided with levetiracetam. There is not a definite case report about hyponatremia and SIADH due to LTG therapy in the literature. However, Mewasingh et al.[5] had reported two different patients with central diabetes insipidus receiving LTG for epileptic seizures whose need for desmopressin decreased after LTG treatment. One of the patients was taking CBZ; after administration of LTG, desmopressin requirement decreased proportionately with the LTG dose. The same patient had discontinued CBZ, but continued to take same dose of desmopressin; however while reducing LTG dose desmopressin requirement was evidently decreased. The second patient reported was using LTG alone when desmopressin needs were noticed to be decreased. The changes in desmopressin requirement was apparent in the following days of change in LTG dose. Kloster et al.[6] reported two patients, an adult and adolescent, who died while using oxcarbazepine and vigabatrin and SIADH was diagnosed during postmortem examinations. One of the patients was using LTG besides but the sudden death and SIADH was attributed to oxcarbazepine. When our case is taken into consideration, the patient was on CBZ therapy for 1 year and had no hyponatremia or decrease in desmopressin need. After administration of LTG development of symptomatic hyponatremia, increase in urine density, sodium and osmolality, hypouricemia and decrease in desmopressin requirement inclined the diagnosis of SIADH. Moreover, hyponatremia did not improve with restriction of fluid uptake, but with discontinuation of LTG and increase in desmopressin dose, serum sodium levels reached normal levels and this confirmed our diagnosis. In conclusion, even if the effect of LTG on fluid and sodium balance is not clear in the literature, it is supposed to increase the central release of vasopressin, such as CBZ. The decrease in patient's desmopressin requirement during LTG therapy supports this theory.
  6 in total

1.  Inappropriate antidiuresis during carbamazepine treatment.

Authors:  K M Flegel; C H Cole
Journal:  Ann Intern Med       Date:  1977-12       Impact factor: 25.391

2.  Hyponatraemia associated with lamotrigine in cranial diabetes insipidus.

Authors:  L Mewasingh; S Aylett; F Kirkham; R Stanhope
Journal:  Lancet       Date:  2000-08-19       Impact factor: 79.321

Review 3.  The syndrome of inappropriate antidiuretic hormone: prevalence, causes and consequences.

Authors:  M J Hannon; C J Thompson
Journal:  Eur J Endocrinol       Date:  2010-02-17       Impact factor: 6.664

4.  Sudden death in two patients with epilepsy and the syndrome of inappropriate antidiuretic hormone secretion (SIADH).

Authors:  R Kloster; H C Børresen; P Hoff-Olsen
Journal:  Seizure       Date:  1998-10       Impact factor: 3.184

Review 5.  A review of drug-induced hyponatremia.

Authors:  George Liamis; Haralampos Milionis; Moses Elisaf
Journal:  Am J Kidney Dis       Date:  2008-05-12       Impact factor: 8.860

Review 6.  Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review.

Authors:  T Van Amelsvoort; R Bakshi; C B Devaux; S Schwabe
Journal:  Epilepsia       Date:  1994 Jan-Feb       Impact factor: 5.864

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.